LEBANON, IN — Fluor Corporation announces that it has received a letter of intent from a pharmaceutical maker to provide engineering, procurement, and construction management (EPCM) services for its Lebanon, Indiana, mega-project. Fluor will recognize the multi-billion-dollar reimbursable contract as a new award in the first quarter of 2025.

This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 2023.

The facility will manufacture groundbreaking peptide-based drugs for Type 2 diabetes and weight control, and it represents the largest investment in an active pharmaceutical ingredient facility in U.S. history.

“This monumental project stands as one of the largest life science endeavors ever undertaken in a single initiative and demonstrates Fluor’s EPCM leadership position in the sector,” said Richard Meserole, President of Fluor’s Advanced Technologies & Life Sciences business. “The products this facility manufactures have the ability to enhance the overall well-being of its users globally. Fluor is honored to be delivering it."

Fluor’s nearly 27,000 employees provide professional and technical solutions that deliver projects to clients around the world. With headquarters in Irving, Texas, Fluor has provided engineering, procurement, and construction services for more than a century.